| First Author | Pathak S | Year | 2020 |
| Journal | PLoS One | Volume | 15 |
| Issue | 6 | Pages | e0234910 |
| PubMed ID | 32559200 | Mgi Jnum | J:293076 |
| Mgi Id | MGI:6435849 | Doi | 10.1371/journal.pone.0234910 |
| Citation | Pathak S, et al. (2020) Brd2 haploinsufficiency extends lifespan and healthspan in C57B6/J mice. PLoS One 15(6):e0234910 |
| abstractText | Aging in mammals is the gradual decline of an organism's physical, mental, and physiological capacity. Aging leads to increased risk for disease and eventually to death. Here, we show that Brd2 haploinsufficiency (Brd2+/-) extends lifespan and increases healthspan in C57B6/J mice. In Brd2+/- mice, longevity is increased by 23% (p<0.0001), and, relative to wildtype animals (Brd2+/+), cancer incidence is reduced by 43% (p<0.001). In addition, relative to age-matched wildtype mice, Brd2 heterozygotes show healthier aging including: improved grooming, extended period of fertility, and lack of age-related decline in kidney function and morphology. Our data support a role for haploinsufficiency of Brd2 in promoting healthy aging. We hypothesize that Brd2 affects aging by protecting against the accumulation of molecular and cellular damage. Given the recent advances in the development of BET inhibitors, our research provides impetus to test drugs that target BRD2 as a way to understand and treat/prevent age-related diseases. |
